Document is current
Any future updates will be listed below
-
Authors
Barksdale, Bryan R.
Enten, Lauren
DeMarco, Annamarie
Kline, Rachel
Doss, Manoj K. https://orcid.org/0000-0003-2939-2522
Nemeroff, Charles B. https://orcid.org/0000-0001-7867-1160
Fonzo, Gregory A. https://orcid.org/0000-0002-0213-1034
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH132784, R01MH129694, R01MH125886, K23MH114023, R01MH117292, R01MH122387, R01MH125886)
One Mind – Baszucki Brain Research Fund, SEAL Future Foundation
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01AA021090)
Texas Child Mental Health Consortium
- License Information
-
More Information
Article History
Received: 20 December 2024
Revised: 4 April 2025
Accepted: 11 April 2025
First Online: 24 April 2025
Competing interests
: GAF has received funds for consulting from Synapse Bio AI and Alto Neuroscience and owns equity in Alto Neuroscience. MKD has received consulting funds from VCENNA. CBN has received funds for consulting from ANeuroTech (division Anima BV), Abbott Laboratories, Signant Health, Janssen Research and Development LLC, BioXcel Therapeutics, Silo Pharma, Engrail Therapeutics, Clexio Bioscience LTD, EcoR1 Capital LLC, EmbarkNeuro (formerly AncoraBio), Galen Mental Health LLC, Goodcap Pharmaceuticals Inc., ITI Inc., LUCY Scientific Discovery, Relmada Therapeutics Inc., Sage Therapeutics Inc., Senseye Inc., Precisement Health, Autobahn Therapeutics Inc., EMA Wellness, Heading Health LLC, Synapse Bio AI, Ninnion, Pasithea, and Skyland Trails. CBN owns stock/equity in Corcept Therapeutics Company, EMA Wellness, Precisement Health, Relmada Therapeutics Inc., Signant Health, Galen Mental Health, and Senseye Inc. CBN is on the steering/advisory board for ANeuroTech (division Anima BV), Signant Health, Laureate Institute for Brain Research (LIBR) Inc., Galen Mental Health LLC, Heading Health LLC, Pasithea Therapeutics Corp., Sage Therapeutics Inc., Senseye Inc., and Skyland Trails. All other authors report no competing interests.
